More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
Proteins Express Health
More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
We leverage health prediction algorithms across healthcare ecosystem
Howard W. Sams
Chief Executive Officer
Previously Global Head of Siemens Digital and Computational Pathology business. Global leadership roles in Roche Diagnostics over a decade. Multiple roles at Guidant/Boston Scientific, started career at Conseco. BS, Butler University & MBA from the University of Notre Dame.
Leena Das-Young, PharmD
SVP, Strategy & Innovations
Led early cancer detection at Guardant Health. Prior Global Head of Pfizer Late Phase Oncology development with multiple leadership roles in commercial & development at Pfizer & Bayer. Pre-industry roles in AIDS clinical research & direct patient care in various health systems. BS & PharmD from Purdue University.
David Perlman, Ph.D.
VP, Head of Proteomics
More than 25 years at the cutting-edge of the Proteomics field. Directed the Ultrasensitive & Single-cell Proteomics biomarker and drug discovery group at Merck. Previously, Head of Target Discovery at Crescenta Biosciences and Director of the Collaborative Proteomics Center at Princeton University. Ph.D. and Post-docs in Cell & Molecular Biology, Virology and Proteomics, BU School of Medicine.
Greer Myers
SVP, Health Markets
More than 25 years of healthcare experience in venture capital and private equity backed businesses. Background spans payer, post-acute, health services, and technology segments within the healthcare vertical. Following successful exits to Humana and CareCentrix in 2020, worked with healthcare companies to assist in product positioning, solution design, and financing. BA, Jepson School of Leadership Studies, University of Richmond.
Michael Powell
VP, Finance
Oversees finance for Health Outlook. Multiple investment banking roles with increasing responsibility. Previously was Director, Healthcare Investment Banking at Cantor Fitzgerald. Previously worked at Jefferies and Merrill Lynch. BS, Brown University. MBA, Columbia Business School.
Tim Opler, Ph.D.
Co-Founder
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role. Ph.D., Econ, UCLA.
Jeremy Bowser
SVP, Operations
Leads our Operations division. Previously led implementation, contracting and commercial education Teams at Roche Diagnostics. Retired Navy SEAL, served 25 years in Naval Special Warfare. Awarded 4 x Bronze Star (twice with valor) and Purple Heart. BS, University of Charleston and is an MBA candidate with University of Chicago Booth School of Business.
Jason Wang
Chief Medical Scientist
Director of the Center for Policy, Outcomes, and Prevention, and Professor of Pediatrics and Health Policy at Stanford University. Co-chairs the mobile health and other new technologies group at the Stanford Center for Population Health Sciences. B.S. in molecular biology from MIT, M.D. from Harvard Medical School, and Ph.D. in policy analysis from RAND.
Lisa Uthgenannt
Head of Human Resources
Seasoned global HR executive with extensive experience in healthcare services, medical devices, pharmaceuticals and chemicals industries. Most recently delivered consulting services to start-up companies. Previously Chief Human Resources Officer at LabCorp and Senior Vice Present of Human Resources at Covance and Johnson & Johnson.
Joseph Konowiecki, J.D.
Chairman,
Alignment Health
As General Counsel for PacifiCare, one of the nation's largest health organizations, he was instrumental in closing its $9.2 billion sale to United Health. He is currently Chairman of Alignment Healthcare, a rapidly growing Medicare insurer. He serves on the board of directors for Health Outlook.
Tadd Wessel
Managing Partner, Petrichor Healthcare Capital Management
Mr. Wessel was formerly a Managing Director at OrbiMed Advisors and Vice President at Fortress Investment Group. He sits on numerous boards of directors of life sciences companies as well as the International Centers for Precision Oncology (ICPO) Foundation. A.B. in Biology from Princeton University.
Adam Morgan
Partner at Avego,
CIO of Velan Capital
Career spanning two decades through the healthcare and fundamental asset management. Before Avego he worked at Broadfin Capital, Iguana Healthcare and Pura Vida Investments. Previous role at Cowen and Company. BS in Chemistry from the University of Minnesota, MBA from the Carlson School of Management at the University of Minnesota.
Peter Koerte, Ph.D.
Chief Technology & Strategy Officer, Siemens
As CTO and CSO for Siemens AG, Peter is responsible for strategy, digitization and establishment of the industrial internet of things (IoT). Peter has had multiple global management roles at Siemen Healthineers and has also worked at BCG. He received a Ph.D. in strategy and international management from WHU Otto Beisheim School of Management.
Howard W. Sams
Chief Executive Officer,
Health Outlook
Previously Global Head of Siemens Digital and Computational Pathology business. Global leadership roles in Roche Diagnostics over a decade. Multiple roles at Guidant/Boston Scientific, started career at Conseco. BS, Butler University & MBA from the University of Notre Dame.
Tim Opler, Ph.D.
Co-Founder,
Health Outlook
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role. Ph.D., Econ, UCLA.
John Rydzewski
Co-Founder,
Health Outlook
Private investor, advisor and director to healthcare companies and health policy organizations following investment banking and asset management careers. Chairman, RAND Health Board of Advisors and a member of the University of Pennsylvania School of Nursing Board of Advisors. MBA and BS from The Wharton School.
Andy Dannenberg, M.D.
Former Professor Medicine,
Weill Cornell Medical College
Partner at Emerald Bioventures. Formerly was Professor of Medicine at Weill Cornell Medical College. Author of 200+ scientific publications. Expert on inflammation and cancer. MD Wash U., St. Louis.
Richard Ulevitch, Ph.D.
Dept. Immunology,
Scripps Research Institute
Richard Ulevitch is professor of immunology and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute. His career is marked by a number of seminal scientific discoveries in the field of innate immunity. He has a strong ongoing interest in implications of proteomics for science and medicine. He received a Ph.D. in Immunology from the University of Pennsylvania.
Paul Ridker, M.D.
Professor of Medicine,
Harvard University
Dr. Ridker is a cardiovascular epidemiologist and biomedical researcher whose research has provided proof-of-principle for the inflammation hypothesis of atherosclerosis and the first proven anti-inflammatory treatment for coronary artery disease.
David Shulkin, M.D.
Former Secretary,
Veterans Administration
Dr. Shulkin is an American physician and former U.S. Secretary of Veterans Affairs. Shulkin was also CEO of Beth Israel Medical Center and was president of Morristown Medical Center. He was the first CMO of the University of Pennsylvania Hospital.
Thomas E. Rohan, M.B.B.S., PH.D., D.H.Sc.
Professor, Department of Epidemiology & Population Health
Dr. Rohan is a cancer epidemiologist who studies the role of genetic/molecular, nutritional, and hormonal factors in the etiology and pathogenesis of a wide range of cancers. In addition to being chair of the department of epidemiology and population health, Dr. Rohan is associate director for population sciences in the Albert Einstein Cancer Center. He is on the editorial board of several journals, and is a member of several professional societies.
Mark Simon
Co-Founder and Advisor,
Torreya
Mark Simon is a partner at Torreya Partners, which he co-founded in 2007. He brings over 20 years of experience in advising biotech companies. He is active on numerous boards including that for the Alliance for Aging Research. Before Torreya, Simon in investment banking at Citigroup and Robertson Stephens. Mark received an MBA from Harvard Business School.
Dan Lewis
Former COO
MetroHealth System
Dan Lewis was COO of The MetroHealth System, a major provider in Ohio, from 2014 to 2018. From 2018 to 2021 he ran Lobesity, a biotech company, through its successful trade sale. Dan received a BA from Kent State and an MA from The University of Akron.
The Health
Prediction Company